drugset / Trial / NCT06773962
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).
Timeline
- Start
- 2025-03-20
- Primary completion
- 2026-11-28
- Completion
- 2026-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TB006 | Monoclonal antibody | — | Intravenous |